Intec Pharma Ltd., a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, has announced the appointment of Jeffrey A Meckler as vice chairman of its board of directors, effective immediately.

"We are delighted to welcome Jeff to the Intec Board," commented John W. Kozarich, Ph.D., chairman of the board of Intech Pharma. "Jeff's rich industry experience and insights into corporate development strategies are renowned in the industry. Our innovative drug delivery platform technology will benefit greatly from Jeff's efforts. In addition, his joining the Intec Pharma team dovetails with our goal to extend the U.S. and global footprint of Intec and enhance the broader recognition of our technology."

Meckler brings to Intec Pharma more than 25 years of life sciences executive experience. Meckler spent more than 17 years at Pfizer, where he held leadership positions in corporate strategic planning, acquisitions and business development, market research, manufacturing systems and sales operations analysis. Most recently, Meckler was chief executive officer of Cocrystal Pharma. Previously, Meckler was a director of QLT, and initially the principal executive officer during its transformation into an orphan drug company. He has served on numerous corporate boards and is currently a director of Retrophin.

"I am eager to be joining the Intec Pharma team," said Jeffrey Meckler. "It will be exciting to help maximize the potential of the Accordion Pill technology and its various therapeutic programs, such as the Parkinson's disease program. I look forward to working with my fellow directors and the management team to help grow Intec Pharma."

Meckler earned his J.D. from Fordham University School of Law and is admitted to the New York Bar. He earned an M.S. in Industrial Administration and a B.S. in Industrial Management from Carnegie Mellon University.

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism.

The company's product pipeline includes four product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients; Accordion Pill Zaleplon, or AP-ZP, which is being developed for the treatment of insomnia, including sleep induction and the improvement of sleep maintenance; an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug (NSAID)-induced ulcers; and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC), which is being developed for various indications including low back neuropathic pain and fibromyalgia.